Big Health spent the week spotlighting SleepioRx, its FDA-cleared prescription digital therapeutic for insomnia, through a coordinated push aimed at healthcare providers. The company is promoting a 30-minute webinar on May 15 that focuses on integrating digital CBT-I into routine clinical workflows.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senior clinical leaders, including the Chief Medical Officer and VP of Clinical Affairs, are slated to discuss clinical evidence, real-world case studies, and specific use cases for SleepioRx. The session will also cover practical issues such as referrals, coverage, and billing, which remain key hurdles for digital therapeutics adoption.
Big Health is emphasizing SleepioRx as a scalable, first-line, non-pharmacologic alternative to traditional insomnia medications. By targeting provider education, the company aims to deepen penetration in clinical settings and encourage more consistent prescribing behavior.
The outreach is also designed to clarify reimbursement pathways and operational models, including direct contracts and embedded referral options for health systems. These efforts are intended to reduce friction for clinicians and payers evaluating how to implement and pay for digital CBT-I solutions.
For Big Health, the week’s activities underscore a strategy centered on clinical validation, workflow integration, and payer alignment rather than direct-to-consumer channels. If provider adoption and payer engagement progress as intended, the initiative could support higher prescription volumes and more predictable recurring revenue.